Medtronic closes 1st phase of Symplicity renal denervation feasibility trial
Medtronic said the 1st phase of a small trial of the next iteration of its Symplicity device for treating high blood pressure showed a 100% success rate.
The 9-patient trial delivered a 100% acute success rate in accessing the renal arteries and delivering the therapy, according to a press release.
"We look forward to moving forward with our clinical evaluation of this next-generation system that aims to augment our portfolio by offering more sophisticated features that should benefit both physicians and patients," Medtronic's president of coronary & renal denervation Sean Salmon said in prepared remarks. "This feasibility study represents Medtronic's commitment to providing physicians with a broader range of solutions for performing renal denervation and to collaborating with physician partners in the ongoing evaluation of this ground-breaking therapy."